Multiple sclerosis, seizures, and antiepileptics: Role of IL-18, IDO, and melatonin

European Journal of Neurology

Volumn 18, Issue 5, 2011, Pages 680-685

  Anderson, G ^a   Rodriguez, M ^b  

^a CRC   (United Kingdom)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Antiepileptic drugs; IDO; IL 18; Melatonin; Multiple sclerosis; Seizures

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; COLECALCIFEROL; GAMMA INTERFERON; HYDROCORTISONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 18; KYNURENINE; LITHIUM; MELATONIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; QUINOLINIC ACID; SEROTONIN; VALPROIC ACID;

BLOOD BRAIN BARRIER; CIRCUMVENTRICULAR ORGAN PERMEABILITY; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; PERMEABILITY; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANTICONVULSANTS; COMORBIDITY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; INTERLEUKIN-18; MELATONIN; MULTIPLE SCLEROSIS; QUINOLINIC ACID; SEIZURES; UP-REGULATION;

EID: 79954572289     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03257.x     Document Type: Review

References (53)

1. Drake WE Jr, Macrae D. Epilepsy and Multiple Sclerosis. Neurology 1961; 11: 810-816.
2. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435-440.
3. Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009; 23: 805-815.
4. Anderson G, Ojalla J. Alzheimer's and seizures: interleukin-18, indoleamine. 2, 3-dioxygenase and quinolinic acid. Int J Tryptophan Res 2010; 3: 169-173.
5. Koch MW, Polman SK, Uyttenboogaart M, De Keyser J. Treatment of seizures in multiple sclerosis. Cochrane Database Syst Rev 2009; 3: CD007150.
6. Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008; 49: 948-953.
7. Losy J, Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol Scand 2001; 104: 171-173.
8. Yu JT, Tan L, Song JH, et al. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease. Brain Res 2009; 9: 1253.
9. Briellmann RS, Torn-Broers Y, Busuttil BE, et al. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology 2000; 3: 435-437.
10. Sadovnick AD, Jacobs DH. MS and cognition and APOE: the ongoing conundrum about biomarkers. Neurology 2008; 3: 164-165.
11. Portaccio E, Zipoli V, Goretti B, et al. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol Scand 2009; 120: 439-441.
12. Portaccio E, Goretti B, Zipoli V, et al. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 1489-1494.
13. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen Synthase Kinase-3 Plays a Central Role in Mediating Glucocorticoid-Induced Apoptosis. Mol Endocrinol 2010; 24: 1136-1150.
14. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2, 3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 2001; 10: 6332-6340.
15. Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem 2008; 105: 1346-1357.
16. André C, O'Connor JC, Kelley KW, Lestage J, Dantzer R, Castanon N. Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2, 3-dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroimmunol 2008; 2: 90-99.
17. Saper CB. The dance of the perivascular and endothelial cells: mechanisms of brain response to immune signalling. Neuron 2010; 1: 4-6.
18. Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Karahalios G, Sfagos C. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J Neurochem 2009; 108: 158-164.
19. Akpinar Z, Tokgöz S, Gökbel H, Okudan N, Uǧuz F, Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 2008; 2: 253-257.
20. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15: 393-403.
21. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010; 1: 84-91.
22. Molina-Carballo A, Muñoz-Hoyos A, Sánchez-Forte M, Uberos-Fernández J, Moreno-Madrid F, Acuña-Castroviejo D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics 2007; 38: 122-125.
23. Chahbouni M, Escames G, Venegas C, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.
24. Lob HE, Marvar PJ, Guzik TJ, et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010; 55: 277-283.
25. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 2007; 48: 5360-5370.
26. Vellinga MM, Geurts JJ, Rostrup E, et al. Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging 2009; 29: 768-773.
27. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008; 14: 1091-1098.
28. Wosik K, Cayrol R, Dodelet-Devillers A, et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007; 34: 9032-9042.
29. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009; 6: 192-199.
30. Lapteva N, Ide K, Nieda M, et al. Activation and suppression of renin-angiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002; 1: 194-200.
31. Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 35: 14948-14953.
32. Lovrecić L, Ristić S, Starcević-Cizmarević N, et al. Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. Acta Neurol Scand 2006; 114: 374-377.
33. Kipp M, Karakaya S, Johann S, Kampmann E, Mey J, Beyer C. Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J Neuroendocrinol 2007; 19: 819-822.
34. Castro LM, Gallant M, Niles LP. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005; 95: 1227-1236.
35. Marinova Z, Ren M, Wendland JR, et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009; 111: 976-987.
36. Zhou R, Gray NA, Yuan P, et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005; 18: 4493-4502.
37. De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008; 1: 338-345.
38. Quiros I, Mayo JC, Garcia-Suarez O, et al. Melatonin prevents the glucocorticoid receptor inhibition of cell proliferation and toxicity in hippocampal cells by reducing the glucocorticoid receptor nuclear translocation. J Steroid Biochem Mol Biol 2008; 110: 116-124.
39. You JM, Yun SJ, Nam KN, Kang C, Won R, Lee EH. Mechanism of glucocorticoid-induced oxidative stress in rat hippocampal slice cultures. Can J Physiol Pharmacol 2009; 87: 440-447.
40. Shini S, Shini A, Kaiser P. Cytokine and chemokine gene expression profiles in heterophils from chickens treated with corticosterone. Stress 2010; 13: 185-194.
41. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 2007; 7: 1317-1322.
42. Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000; 6: 3099-3104.
43. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118: 2562-2573.
44. Zhang J, Lee SM, Shannon S, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009; 119: 3048-3058.
45. Lan MJ, Yuan P, Chen G, Manji HK. Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate. J Mol Neurosci 2008; 35: 225-234.
46. Bright JJ, Walline CC, Kanakasabai S, Chakraborty S. Targeting PPAR as a therapy to treat multiple sclerosis. Expert Opin Ther Targets 2008; 12: 1565-1575.
47. Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004; 1: 3.
48. Alonso-Vale MI, Peres SB, Vernochet C, Farmer SR, Lima FB. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J Pineal Res 2009; 47: 221-227.
49. Klotz L, Burgdorf S, Dani I, et al. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009; 206: 2079-2089. Epub 2009 Sep 8. Erratum in: J Exp Med. 2009 Dec 21;206(13):3159.
50. Shi G, Ramaswamy M, Vistica BP, et al. Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J Immunol 2009; 11: 7547-7556.
51. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175.
52. Wei-guo Z, Hui Y, Shan L, et al. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways. Immunol Cell Biol 2010; 88: 305-312.
53. Cumiskey D, Curran BP, Herron CE, O'Connor JJ. A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology 2007; 52: 1616-1623.